<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03338387</url>
  </required_header>
  <id_info>
    <org_study_id>AZV Grant Agency</org_study_id>
    <nct_id>NCT03338387</nct_id>
  </id_info>
  <brief_title>GH-PP-Ghrelin Loop and Sympathicolysis in Bulimia</brief_title>
  <official_title>Acipimox Exerts Co-Feedback of GH, PP Family and Leptin on Ghrelin With Beta Sympathicolysis in Bulimia: Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charles University, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of Acipimox or placebo to exercise on growth hormone
      release and ghrelin secretion in bulimic patients and in healthy women. Two groups of
      participants will receive Acipimox together with exercise versus identical placebo with
      exercise.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acipimox and exercise each increase growth hormone release, but they do so by different
      mechanisms.

      Acipimox is an anti-lipolytic drug and increases growth hormone release by decreasing free
      fatty acids levels and that Acipimox may exert to a negative feedback of growth hormone on
      ghrelin.

      Physical exercise is a potent physiological stimulus for growth hormone release. As ghrelin
      has a stimulatory effect on growth hormone secretion, growth hormone may inhibit circulating
      ghrelin levels via a feedback loop. Growth hormone stimulates lipolysis and resultant free
      fatty acids may suppress ghrelin secretion.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 6, 2003</start_date>
  <completion_date type="Anticipated">January 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 16, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in plasma growth hormone levels</measure>
    <time_frame>baseline and over a total 2 weeks</time_frame>
    <description>Plasma growth hormone (mIU/L) levels will be measured by a commercial RIA kit in the morning and after exercise alone or together with Acipimox administration over a total of 2 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in extracellular adipose tissue glycerol levels</measure>
    <time_frame>baseline and over a total 2 weeks</time_frame>
    <description>Extracellular adipose tissue glycerol (umol/L) levels will be measured using microdialysis technique and analyzed with a radiometric kit in the morning and after exercise alone or together with Acipimox administration over a total of 2 weeks.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in body mass index (BMI)</measure>
    <time_frame>baseline and over a total 2 weeks</time_frame>
    <description>Weight in kilograms and height in meters will be measured in the morning and after exercise alone or together with Acipimox administration over a total of 2 weeks. Weight and height will be combined to report BMI in kg/m2.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Eating Disorder</condition>
  <condition>Bulimia Nervosa</condition>
  <arm_group>
    <arm_group_label>Acipimox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Other Names: Olbetam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Other Names:
Placebo (for Olbetam)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acipimox</intervention_name>
    <description>Acipimox</description>
    <arm_group_label>Acipimox</arm_group_label>
    <other_name>5-methylpyrazine-2-carboxylic acid 4-oxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Other Names: Placebo (for Olbetam)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Cellulose pills manufactured to mimic Acipimox 250Mg Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of bulimia nervosa

          -  Body mass index (BMI) between 18 and 23 kg/m2

        Exclusion Criteria:

          -  History of heart disease

          -  History of bleeding disorders

          -  Subjects with diabetes type 1 or 2, hypo- or hyperthyroidism

          -  Subjects with hepatogastroenteric disease

          -  Pregnant, trying to become pregnant or breast feeding

          -  Patients with other psychiatric diseases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kvido Smitka, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles University</affiliation>
  </overall_official>
  <reference>
    <citation>Nedvidkova J, Smitka K, Papezova H, Vondra K, Hill M, Hainer V. Acipimox during exercise points to an inhibitory feedback of GH on ghrelin secretion in bulimic and healthy women. Regul Pept. 2011 Feb 25;167(1):134-9. doi: 10.1016/j.regpep.2010.12.012. Epub 2011 Jan 13.</citation>
    <PMID>21237212</PMID>
  </reference>
  <reference>
    <citation>Smitka K, Papezova H, Vondra K, Hill M, Hainer V, Nedvidkova J. A higher response of plasma neuropeptide Y, growth hormone, leptin levels and extracellular glycerol levels in subcutaneous abdominal adipose tissue to Acipimox during exercise in patients with bulimia nervosa: single-blind, randomized, microdialysis study. Nutr Metab (Lond). 2011 Nov 17;8(1):81. doi: 10.1186/1743-7075-8-81.</citation>
    <PMID>22093818</PMID>
  </reference>
  <reference>
    <citation>Smitka K, Papezova H, Vondra K, Hill M, Hainer V, Nedvidkova J. Short-term exercise combined with Acipimox administration induces an increase in plasma ACTH and its subsequent fall in the recovery phase in bulimic women. Regul Pept. 2013 Mar 10;182:45-52. doi: 10.1016/j.regpep.2012.12.010. Epub 2013 Jan 11.</citation>
    <PMID>23318497</PMID>
  </reference>
  <reference>
    <citation>Smitka K, Papezova H, Vondra K, Hill M, Hainer V, Nedvidkova J. The role of &quot;mixed&quot; orexigenic and anorexigenic signals and autoantibodies reacting with appetite-regulating neuropeptides and peptides of the adipose tissue-gut-brain axis: relevance to food intake and nutritional status in patients with anorexia nervosa and bulimia nervosa. Int J Endocrinol. 2013;2013:483145. doi: 10.1155/2013/483145. Epub 2013 Sep 9. Review.</citation>
    <PMID>24106499</PMID>
  </reference>
  <reference>
    <citation>Smitka K, Marešová D. Adipose Tissue as an Endocrine Organ: An Update on Pro-inflammatory and Anti-inflammatory Microenvironment. Prague Med Rep. 2015;116(2):87-111. doi: 10.14712/23362936.2015.49. Review.</citation>
    <PMID>26093665</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles University, Czech Republic</investigator_affiliation>
    <investigator_full_name>Kvido Smitka</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>neuropeptides</keyword>
  <keyword>microdialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Bulimia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acipimox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

